Cargando…
Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients
BACKGROUND: Recent studies have suggested that deregulated AKT1 signaling is associated with schizophrenia. We hypothesized that if this is indeed the case, we should observe both decreased AKT1 expression as well as deregulation of AKT1 regulated pathways in Peripheral Blood Mononuclear Cells (PBMC...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290567/ https://www.ncbi.nlm.nih.gov/pubmed/22393424 http://dx.doi.org/10.1371/journal.pone.0032618 |
_version_ | 1782225018101432320 |
---|---|
author | van Beveren, Nico J. M. Buitendijk, Gabrielle H. S. Swagemakers, Sigrid Krab, Lianne C. Röder, Christian de Haan, Lieuwe van der Spek, Peter Elgersma, Ype |
author_facet | van Beveren, Nico J. M. Buitendijk, Gabrielle H. S. Swagemakers, Sigrid Krab, Lianne C. Röder, Christian de Haan, Lieuwe van der Spek, Peter Elgersma, Ype |
author_sort | van Beveren, Nico J. M. |
collection | PubMed |
description | BACKGROUND: Recent studies have suggested that deregulated AKT1 signaling is associated with schizophrenia. We hypothesized that if this is indeed the case, we should observe both decreased AKT1 expression as well as deregulation of AKT1 regulated pathways in Peripheral Blood Mononuclear Cells (PBMCs) of schizophrenia patients. OBJECTIVES: To examine PBMC expression levels of AKT1 in schizophrenia patients versus controls, and to examine whether functional biological processes in which AKT1 plays an important role are deregulated in schizophrenia patients. METHODS/RESULTS: A case-control study, investigating whole-genome PBMC gene expression in male, recent onset (<5 years) schizophrenia patients (N = 41) as compared to controls (N = 29). Genes, differentially expressed between patients and controls were identified using ANOVA with Benjamini-Hochberg correction (false discovery rate (FDR) = 0.05). Functional aspects of the deregulated set of genes were investigated with the Ingenuity Pathway Analysis (IPA) Software Tool. We found significantly decreased PBMC expression of AKT1 (p<0.001, t = −4.25) in the patients. AKT1 expression was decreased in antipsychotic-free or -naive patients (N = 11), in florid psychotic (N = 20) and in remitted (N = 21) patients. A total of 1224 genes were differentially expressed between patients and controls (FDR = 0.05). Functional analysis of the entire deregulated gene set indicated deregulated canonical pathways involved in a large number of cellular processes: immune system, cell adhesion and neuronal guidance, neurotrophins and (neural) growth factors, oxidative stress and glucose metabolism, and apoptosis and cell-cycle regulation. Many of these processes are associated with AKT1. CONCLUSIONS: We show significantly decreased PBMC gene expression of AKT1 in male, recent-onset schizophrenia patients. Our observations suggest that decreased PBMC AKT1 expression is a stable trait in recent onset, male schizophrenia patients. We identified several AKT related cellular processes which are potentially affected in these patients, a majority of which play a prominent role in current schizophrenia hypotheses. |
format | Online Article Text |
id | pubmed-3290567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32905672012-03-05 Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients van Beveren, Nico J. M. Buitendijk, Gabrielle H. S. Swagemakers, Sigrid Krab, Lianne C. Röder, Christian de Haan, Lieuwe van der Spek, Peter Elgersma, Ype PLoS One Research Article BACKGROUND: Recent studies have suggested that deregulated AKT1 signaling is associated with schizophrenia. We hypothesized that if this is indeed the case, we should observe both decreased AKT1 expression as well as deregulation of AKT1 regulated pathways in Peripheral Blood Mononuclear Cells (PBMCs) of schizophrenia patients. OBJECTIVES: To examine PBMC expression levels of AKT1 in schizophrenia patients versus controls, and to examine whether functional biological processes in which AKT1 plays an important role are deregulated in schizophrenia patients. METHODS/RESULTS: A case-control study, investigating whole-genome PBMC gene expression in male, recent onset (<5 years) schizophrenia patients (N = 41) as compared to controls (N = 29). Genes, differentially expressed between patients and controls were identified using ANOVA with Benjamini-Hochberg correction (false discovery rate (FDR) = 0.05). Functional aspects of the deregulated set of genes were investigated with the Ingenuity Pathway Analysis (IPA) Software Tool. We found significantly decreased PBMC expression of AKT1 (p<0.001, t = −4.25) in the patients. AKT1 expression was decreased in antipsychotic-free or -naive patients (N = 11), in florid psychotic (N = 20) and in remitted (N = 21) patients. A total of 1224 genes were differentially expressed between patients and controls (FDR = 0.05). Functional analysis of the entire deregulated gene set indicated deregulated canonical pathways involved in a large number of cellular processes: immune system, cell adhesion and neuronal guidance, neurotrophins and (neural) growth factors, oxidative stress and glucose metabolism, and apoptosis and cell-cycle regulation. Many of these processes are associated with AKT1. CONCLUSIONS: We show significantly decreased PBMC gene expression of AKT1 in male, recent-onset schizophrenia patients. Our observations suggest that decreased PBMC AKT1 expression is a stable trait in recent onset, male schizophrenia patients. We identified several AKT related cellular processes which are potentially affected in these patients, a majority of which play a prominent role in current schizophrenia hypotheses. Public Library of Science 2012-02-29 /pmc/articles/PMC3290567/ /pubmed/22393424 http://dx.doi.org/10.1371/journal.pone.0032618 Text en van Beveren et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article van Beveren, Nico J. M. Buitendijk, Gabrielle H. S. Swagemakers, Sigrid Krab, Lianne C. Röder, Christian de Haan, Lieuwe van der Spek, Peter Elgersma, Ype Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title | Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title_full | Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title_fullStr | Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title_full_unstemmed | Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title_short | Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients |
title_sort | marked reduction of akt1 expression and deregulation of akt1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290567/ https://www.ncbi.nlm.nih.gov/pubmed/22393424 http://dx.doi.org/10.1371/journal.pone.0032618 |
work_keys_str_mv | AT vanbeverennicojm markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT buitendijkgabriellehs markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT swagemakerssigrid markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT krabliannec markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT roderchristian markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT dehaanlieuwe markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT vanderspekpeter markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients AT elgersmaype markedreductionofakt1expressionandderegulationofakt1associatedpathwaysinperipheralbloodmononuclearcellsofschizophreniapatients |